|
1
|
Goldhirsch A, Wood WC, Gelber RD, Coates
AS, Thürlimann B and Senn HJ; 10th St. Gallen conference. Progress
and promise: highlights of the international expert consensus on
the primary therapy of early breast cancer 2007. Ann Oncol.
18:1133–1144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kaufmann M, Hortobagyi GN, Goldhirsch A,
et al: Recommendations from an international expert panel on the
use of neoadjuvant (primary) systemic treatment of operable breast
cancer: an update. J Clin Oncol. 24:1940–1949. 2006. View Article : Google Scholar
|
|
3
|
Du C, Fang M, Li Y, Li L and Wang X: Smac,
a mitochondrial protein that promotes cytochrome c-dependent
caspase activation by eliminating IAP inhibition. Cell. 102:33–42.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Verhagen AM, Ekert PG, Pakusch M, et al:
Identification of DIABLO, a mammalian protein that promotes
apoptosis by binding to and antagonizing IAP proteins. Cell.
102:43–53. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goyal L: Cell death inhibition: keeping
caspases in check. Cell. 104:805–808. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song Z, Yao X and Wu M: Direct interaction
between survivin and Smac/DIABLO is essential for the
anti-apoptotic activity of survivin during taxol-induced apoptosis.
J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sobin LH and Wittekind C: TNM
classification of malignant tumours. 6th edition. Wiley-Liss; New
York, NY: pp. 22–26. 2002
|
|
8
|
Mazouni C, Peintinger F, Wan-Kau S, et al:
Residual ductal carcinoma in situ in patients with complete
eradication of invasive breast cancer after neoadjuvant
chemotherapy does not adversely affect patient outcome. J Clin
Oncol. 25:2650–2655. 2007. View Article : Google Scholar
|
|
9
|
Martinez-Ruiz G, Maldonado V,
Ceballos-Cancino G, Grajeda JP and Melendez-Zajgla J: Role of
Smac/DIABLO in cancer progression. J Exp Clin Cancer Res.
27:482008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bank A, Wang P, Du C, Yu J and Zhang L:
SMAC mimetics sensitize nonsteroidal anti-inflammatory drug-induced
apoptosis by promoting caspase-3-mediated cytochrome c release.
Cancer Res. 68:276–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun Q, Zheng X, Zhang L and Yu J: Smac
modulates chemosensitivity in head and neck cancer cells through
the mitochondrial apoptotic pathway. Clin Cancer Res. 17:2361–2372.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Zhou L, Huang J, et al: Role of Smac
in determining the chemotherapeutic response of esophageal squamous
cell carcinoma. Clin Cancer Res. 17:5412–5422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fandy TE, Shankar S and Srivastava RK:
Smac/DIABLO enhances the therapeutic potential of chemotherapeutic
drugs and irradiation, and sensitizes TRAIL-resistant breast cancer
cells. Mol Cancer. 7:602008. View Article : Google Scholar
|
|
14
|
McNeish IA, Bell S, McKay T, Tenev T,
Marani M and Lemoine NR: Expression of Smac/DIABLO in ovarian
carcinoma cells induces apoptosis via a caspase-9-mediated pathway.
Exp Cell Res. 286:186–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mizutani Y, Nakanishi H, Yamamoto K, et
al: Downregulation of Smac/DIABLO expression in renal cell
carcinoma and its prognostic significance. J Clin Oncol.
23:448–454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fulda S, Wick W, Weller M and Debatin KM:
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced
apoptosis and induce regression of malignant glioma in vivo. Nat
Med. 8:808–815. 2002.PubMed/NCBI
|
|
17
|
Blanc-Brude OP, Mesri M, Wall NR, Plescia
J, Dohi T and Altieri DC: Therapeutic targeting of the survivin
pathway in cancer: initiation of mitochondrial apoptosis and
suppression of tumor-associated angiogenesis. Clin Cancer Res.
9:2683–2692. 2003.
|
|
18
|
Shinohara ET, Gonzalez A, Massion PP, et
al: Nuclear survivin predicts recurrence and poor survival in
patients with resected nonsmall cell lung carcinoma. Cancer.
103:1685–1692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Falleni M, Pellegrini C, Marchetti A, et
al: Survivin gene expression in early-stage non-small cell lung
cancer. J Pathol. 200:620–626. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rexhepaj E, Jirstrom K, O’Connor DP, et
al: Validation of cytoplasmic-to-nuclear ratio of survivin as an
indicator of improved prognosis in breast cancer. BMC Cancer.
10:6392010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chu JS, Shew JY and Huang CS:
Immunohistochemical analysis of survivin expression in primary
breast cancers. J Formos Med Assoc. 103:925–931. 2004.PubMed/NCBI
|
|
22
|
Span PN, Sweep FC, Wiegerinck ET, et al:
Survivin is an independent prognostic marker for risk
stratification of breast cancer patients. Clin Chem. 50:1986–1993.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hayashi N, Asano K, Suzuki H, et al:
Adenoviral infection of survivin antisense sensitizes prostate
cancer cells to etoposide in vivo. Prostate. 65:10–19. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boidot R, Vegran F and Lizard-Nacol S:
Predictive value of survivin alternative transcript expression in
locally advanced breast cancer patients treated with neoadjuvant
chemotherapy. Int J Mol Med. 23:285–291. 2009.
|
|
25
|
Estevez GL, Fortes JL, Adrover E, et al:
Doxorubicin and cyclophosphamide followed by weekly docetaxel as
neoadjuvant treatment of early breast cancer: analysis of
biological markers in a GEICAM phase II study. Clin Transl Oncol.
11:54–59. 2009. View Article : Google Scholar
|
|
26
|
Darb-Esfahani S, Loibl S, Müller BM, et
al: Identification of biology-based breast cancer types with
distinct predictive and prognostic features: role of steroid
hormone and HER2 receptor expression in patients treated with
neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer
Res. 11:R692009. View
Article : Google Scholar
|
|
27
|
Liedtke C, Mazouni C, Hess KR, et al:
Response to neoadjuvant therapy and long-term survival in patients
with triple-negative breast cancer. J Clin Oncol. 26:1275–1281.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bear HD, Anderson S, Brown A, et al: The
effect on tumor response of adding sequential preoperative
docetaxel to preoperative doxorubicin and cyclophosphamide:
preliminary results from National Surgical Adjuvant Breast and
Bowel Project Protocol B-27. J Clin Oncol. 21:4165–4174. 2003.
View Article : Google Scholar
|
|
29
|
Colleoni M, Viale G, Zahrieh D, et al:
Chemotherapy is more effective in patients with breast cancer not
expressing steroid hormone receptors: a study of preoperative
treatment. Clin Cancer Res. 10:6622–6628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kennedy SM, O’Driscoll L, Purcell R, et
al: Prognostic importance of survivin in breast cancer. Br J
Cancer. 88:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie W, Jiang P, Miao L, et al: Novel link
between E2F1 and Smac/DIABLO: proapoptotic Smac/DIABLO is
transcriptionally upregulated by E2F1. Nucleic Acids Res.
34:2046–2055. 2006. View Article : Google Scholar : PubMed/NCBI
|
